Unipolare Depression Langfassung - Versorgungsleitlinien.de

439. Dalery J, Aubin V. Etude comparative de la paroxetine et de la mianserine dans la depression
du sujet age: efficacite, tolerance, serotoninodependance. Encephale 2001;27(1):71-81.
440. Clayton AH, Croft HA, Horrigan JP, Wightman DS, Krishen A, Richard NE, Modell JG.
Bupropion extended release compared with escitalopram: effects on sexual functioning and
antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. J Clin
Psychiatry 2006;67(5):736-46.
441. Laux G. Verträglichkeitsprofil von Agomelatin. Psychopharmakother 2009;(19 Suppl):11-4.
442. Montgomery SA. Major depressive disorders: clinical efficacy and tolerability of agomelatine, a
new melatonergic agonist. Eur Neuropsychopharmacol 2006;16:633-8.
443. Bauer M, Crossley NA, Gerber S, Bschor T. The acute antidepressive effects of lithium: from
monotherapy to augmentation therapy in major depression. In: Bauer M, Grof P, Müller-
Oerlinghausen B, editors. Lithium in neuropsychiatry. London: Informa healthcare; 2006. p.
109-27
444. Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for
depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin
Psychiatry 2007;68(6):935-40.
445. Kessing LV, Sondergard L, Kvist K, Andersen PK. Suicide risk in patients treated with lithium.
Arch Gen Psychiatry 2005;62(8):860-6.
446. Baldessarini RJ, Tondo L, Hennen J. Lithium treatment and suicide risk in major affective
disorders: update and new findings. J Clin Psychiatry 2003;64 Suppl 5:44-52.
447. Cipriani A, Pretty H, Hawton K, Geddes JR. Lithium in the prevention of suicidal behavior and
all-cause mortality in patients with mood disorders: a systematic review of randomized trials.
Am J Psychiatry 2005;162(10):1805-19.
448. Guzzetta F, Tondo L, Centorrino F, Baldessarini RJ. Lithium treatment reduces suicide risk in
recurrent major depressive disorder. J Clin Psychiatry 2007;68(3):380-3.
449. Tondo L, Hennen J, Baldessarini RJ. Lower suicide risk with long-term lithium treatment in
major affective illness: a meta-analysis. Acta Psychiatr Scand 2001;104(3):163-72.
450. Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D. St John's wort for
depression--an overview and meta-analysis of randomised clinical trials. BMJ
1996;313(7052):253-8.
451. Linde K, Mulrow CD. St John's wort for depression. Cochrane Database Syst Rev
2000;(2):CD000448.
452. Bauer M, Whybrow PC, Angst J, Versiani M, Moller HJ. World Federation of Societies of
Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive
Disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J Biol
Psychiatry 2002;3(1):5-43.
453. Deltito J, Beyer D. The scientific, quasi-scientific and popular literature on the use of St. John's
Wort in the treatment of depression. J Affect Disord 1998;51(3):345-51.
454. Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St John's wort) in
major depressive disorder: a randomized controlled trial. JAMA 2002;287(14):1807-14.
455. Shelton RC, Keller MB, Gelenberg A, Dunner DL, Hirschfeld R, Thase ME, Russell J, Lydiard
RB, Crits-Christoph P, Gallop R, Todd L, Hellerstein D, Goodnick P, Keitner G, Stahl SM,
Halbreich U. Effectiveness of St John's wort in major depression: a randomized controlled
trial. JAMA 2001;285(15):1978-86.
456. Linde K, Berner MM, Kriston L. St John's wort for major depression. Cochrane Database Syst
Rev 2008;(4):CD000448.
457. Kolkmann R. Phytopharmaka: Qualität und Vergleich. PZ 1996;141:4424-7.
458. Müller WE. Welches Johanniskrautpräparat soll ich verordnen? Psychopharmakother
2000;7:40.
459. Knuppel L, Linde K. Adverse effects of St. John's Wort: a systematic review. J Clin Psychiatry
2004;65(11):1470-9.
© 2009 223